MBX Biosciences, Inc. 8-K

What Happened MBX Biosciences, Inc. (MBX) announced in an 8-K that, effective January 20, 2026, the board appointed Laurie Stelzer as an independent director and designated her a Class I director through the 2028 Annual Meeting of Stockholders. The board increased its size to eight directors to fill an existing vacancy. Ms. Stelzer was also named chair of the Audit Committee and appointed to the Compensation Committee.

Key Details

• Appointment effective: January 20, 2026.
• Term designation: Class I director to serve until the Company’s 2028 Annual Meeting.
• Board size: increased to eight directors to accommodate the appointment.
• Committees: named Chair of the Audit Committee (replacing Ed Mathers) and member of the Compensation Committee.
• Compensation & protections: will receive the same non-employee director pay described in MBX’s Sept. 12, 2024 prospectus; the company will enter into its standard director indemnification agreement.
• No related-party transactions or arrangements requiring Item 404 disclosure were identified. A press release announcing the appointment was issued Jan. 22, 2026.

Why It Matters A new independent Audit Committee chair can affect oversight of MBX’s financial reporting and controls, which is material to investors monitoring governance and risk. The appointment fills a board vacancy and updates committee leadership without indicating any related-party concerns; compensation and indemnification follow the company’s standard policies.